866-997-4948(US-Canada Toll Free)

Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2014-2019

Published By :

Current Partnering

Published Date : Sep 2019

Category :

Pharmaceutical

No. of Pages : 1000 Pages

The Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2014-2019 provides comprehensive understanding and unprecedented access to clinical stage partnering agreements entered into by the worlds leading biopharma companies
Executive Summary

Chapter 1 Introduction

Chapter 2 Why do companies partner clinical stage compounds?

2.1. Introduction
2.2. The role of clinical stage partnering
2.2.1. In-licensing at clinical stage
2.2.2. Out-licensing at clinical stage
2.3. Difference between phase I, II and III stage deals
2.4. Reasons for entering into clinical stage partnering deals
2.4.1. Licensors reasons for entering clinical stage deals
2.4.2. Licensees reasons for entering clinical stage deals
2.5. The future of clinical stage partnering deals

Chapter 3 Clinical stage deal strategies and structure

3.1. Introduction
3.2. At what stage do companies partner?
3.2.1. Partnering early in pharmaceutical/biotech
3.2.1.1. Discovery and preclinical stage partnering case studies
3.2.1.1.a. Case study: LEO Pharma - 4SC
3.2.1.1.b. Case study: Heptares Therapeutics - Cubist
3.2.1.1.c. Case study: Incyte Agenus Bio
3.2.1.1.d. Case study: Janssen Pharmaceutical - Evotec
3.2.2. Partnering later in pharmaceutical/biotech
3.2.2.1. Clinical stage partnering case studies
3.2.2.1.a. Case study: Servier GeNeuro
3.2.2.1.b. Case study: Teva Xenon Pharmaceuticals
3.2.2.1.c. Case study: AstraZeneca - Ardelyx
3.2.2.1.d. Case study: Baxter Onconova Therapeutics
3.3. Early and later stage partnering a risk/cost comparison
3.4. What do companies spend on clinical stage partnering?
3.5. Pure versus multi-component partnering deals
3.6. Pure licensing agreement structure
3.6.1. Example pure licensing agreements
3.6.1.a. Case study : Argos Therapeutics Medinet
3.6.1.b. Case study : Pfizer - GlycoMimetics
3.7. Multicomponent clinical stage partnering agreements
3.7.1. Example multicomponent clinical stage clauses
3.7.1.a. Case study: Gilead Sciences GlobeImmune

Chapter 4 Clinical stage partnering payment strategies

4.1. Introduction
4.2. Clinical stage payment strategies
4.3. Payment options
4.3.1. Headline values
4.3.2. Upfront payments
4.3.2.1. Conditionality of upfront payments
4.3.3. Loans
4.3.4. Convertible loans
4.3.5. Equity
4.3.6. R&D funding
4.3.7. Licensing fees
4.3.8. Milestone payments
4.3.9. Royalty payments
4.3.9.1. Issues affecting royalty rates
4.3.9.2. Royalties on combination products
4.3.9.2.a. Case study: Scripps Research Institute-Cyanotech
4.3.9.3. Guaranteed minimum/maximum annual payments
4.3.9.4. Royalty stacking
4.3.9.5. Royalties and supply/purchase contracts
4.3.10. Quids
4.3.11. Option payments

Chapter 5 Trends in clinical stage deal making

5.1. Introduction
5.2. Clinical stage partnering over the years
5.2.1. Trends in phase I deals since 2014
5.2.1.1. Attributes of phase I deals
5.2.2. Trends in phase II deals since 2014
5.2.2.2. Attributes of phase II deals
5.2.3. Trends in phase III deals since 2014
5.2.3.1. Attributes of phase III deals
5.3. Clinical stage partnering by deal type
5.4. Clinical stage partnering by disease type
5.5. Partnering by clinical stage technology type
5.6. Clinical stage partnering by most active company since 2014

Chapter 6 Payment terms for clinical stage partnering

6.1. Introduction
6.2. Guidelines for clinical stage payment terms
6.2.1. Upfront payments
6.2.2. Milestone payments
6.2.3. Royalty payments
6.3. Clinical stage payment terms deal data analysis
6.3.1. Public data
6.3.2. Survey data
6.4. Payment terms analysis
6.4.1. Clinical stage partnering headline values
6.4.2. Clinical stage deal upfront payments
6.4.3. Clinical stage deal milestone payments
6.4.4. Clinical stage royalty rates
6.5 Clinical stage median financials
6.5.1. Clinical stage headline value
6.5.2. Clinical stage upfront value
6.5.3. Clinical stage milestone value
6.5.4. Clinical stage royalty value

Chapter 7 Leading clinical stage deals

7.1. Introduction
7.2. Top clinical stage deals by value

Chapter 8 Top 25 most active clinical stage dealmakers

8.1. Introduction
8.2. Top 25 most active clinical stage dealmakers

Chapter 9 Clinical stage partnering contracts directory

9.1. Introduction
9.2. Clinical stage deals with contracts since 2014

Chapter 10 Clinical stage deal making by development stage

10.1. Introduction
10.2. Deals by clinical stage
Phase I
Phase II
Phase III
Regulatory
Formulation

Appendices

Appendix 1 Clinical stage dealmaking by companies A-Z
Appendix 2 Clinical stage dealmaking by industry sector
Appendix 3 Clinical stage dealmaking by stage of development
Appendix 4 Clinical stage dealmaking by therapy area
Appendix 5 Clinical stage dealmaking by technology type

About Wildwood Ventures

Current Partnering
Current Agreements
Recent report titles from Current Partnering

Table of figures

Figure 1: Definition of clinical phases in dealmaking
Figure 2: Agreements signed by phase of development (2014- 2019), % of all deals
Figure 3: Components of the pure licensing deal structure
Figure 4: Payment options for clinical stage partnering deals
Figure 5: Issues affecting royalty rates
Figure 6: Clinical stage partnering frequency since 2014
Figure 7: Phase I clinical stage partnering since 2014
Figure 8: Phase II clinical stage partnering since 2014
Figure 9: Phase III clinical stage partnering since 2014
Figure 10: Clinical stage partnering by deal type since 2014
Figure 11: Clinical stage partnering by disease type since 2014
Figure 12: Clinical stage partnering by technology type since 2014
Figure 13: Top 25 most active clinical stage dealmakers since 2014
Figure 14: Review of upfront payments for clinical stage deals
Figure 15: Review of milestone payments for clinical stage deals
Figure 16: Review of royalty payments for clinical stage deals
Figure 17: Clinical stage deals with a headline value
Figure 18: Clinical stage deals with an upfront value
Figure 19: Clinical stage deals with a milestone value
Figure 20: Clinical stage deals with a royalty rate value
Figure 21: Summary median headline value by clinical stage of development since 2014
Figure 22: Summary median upfront payments by clinical stage of development since 2014
Figure 23: Summary median milestone payments by stage of development since 2014
Figure 24: Summary median royalty rate by stage of development since 2014
Figure 25: Top clinical stage deals by value since 2014
Figure 26: Most active clinical stage dealmakers since 2014

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *